Nix raises $10M to license its hydration data to health apps
What's the deal? Nix BiosensorsDealroom has a profile for this one. Try Dealroom → has closed US$6.47M Series A to expand its sweat-sensing hydration technology and push its personalised hydration data into consumer health platforms. The round brings the company's total funding to $17 million.
Who's backing it? Investors include Shorewind CapitalDealroom has a profile for this one. Try Dealroom →, Great Oaks Venture Capital, and White Road InvestmentsDealroom has a profile for this one. Try Dealroom →, the family office of CLIF BarDealroom has a profile for this one. Try Dealroom → founders Gary Erickson and Kit Crawford. Anne WojcickiDealroom has a profile for this one. Try Dealroom →, Len BlavatnikDealroom has a profile for this one. Try Dealroom →, and owners of teams including the St. Louis Blues, Boston Celtics, Baltimore Orioles, and Texas Rangers also joined.
What's the endgame? NixDealroom has a profile for this one. Try Dealroom → builds sweat sensors used across sports, military, occupational, and consumer markets to measure fluid and electrolyte loss in real time. Years of field deployments have produced a dataset the company now wants to sell as software.
Why now? The money will fund Nix Health, an algorithmic product that licenses the company's hydration recommendations to existing health and wellness platforms — no Nix sensor required. That expands its model beyond hardware and into a much larger audience.
"This funding allows us to bring that intelligence to a much larger audience through Nix Health," founder and chief executive officer Meridith Cass said.
For Shorewind, the dataset was the draw. "Nix has spent years deploying its platform across sports, military, and labor, understanding exactly how human physiology responds in a wide range of environments," founding partner Nick Fragnito said, adding it "could not be accomplished in a lab."
What's next? The round will also fund research into other biomarkers detectable through sweat, including lactate, cortisol, glucose, Vitamin D, testosterone, and estrogen. Nix gave no timeline for products based on them.
The signal: At $10 million, the round sits in the roughly 28th percentile by size — modest capital for a company betting that its real-world data, not new hardware, is the asset worth scaling.
Read more: citybiz.co
Image credit: Healthy Living
